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Abstract
Cytochromes P450 metabolize arachidonic acid (AA) into two vasoactive oxylipins with
opposing biologic effects: epoxyeicosatrienoic acids (EETs) and omega-(ω)-terminal hydro-
xyeicosatetraenoic acids (HETEs). EETs have numerous beneficial physiological effects,
including vasodilation and protection against ischemia/reperfusion injury, whereasω-terminal
HETEs induce vasoconstriction and vascular dysfunction. We evaluated the effect of these
oxylipins on post-ischemic vasodilation known as coronary reactive hyperemia (CRH). CRH
prevents the potential harm associated with transient ischemia. The beneficial effects of
EETs are reduced after their hydrolysis to dihydroxyeicosatrienoic acids (DHETs) by soluble
epoxide hydrolase (sEH).ω-terminal HETEs are formed byω-hydroxylase family members.
The relationship among endothelial over-expression of sEH (Tie2-sEH Tr), the changes in
oxylipins it may produce, the pharmacologic inhibition ofω-hydroxylases, activation of
PPARγ, and CRH response to a brief ischemia is not known. We hypothesized that CRH is
attenuated in isolated mouse hearts with endothelial sEH over-expression through modula-
tion of oxylipin profiles, whereas both inhibition ofω-hydroxylases and activation of PPARγ
enhance CRH. Compared to WT mice, Tie2-sEH Tr mice had decreased CRH, including
repayment volume, repayment duration, and repayment/debt ratio (P < 0.05), whereas inhibi-
tion ofω-hydroxylases increased these same CRH parameters in Tie2-sEH Tr mice. Inhibi-
tion of sEH with t-AUCB reversed the decreased CRH in Tie2-sEH Tr mice. Endothelial over-
expression of sEH significantly changed oxylipin profiles, including decreases in DHETs,
mid-chain HETEs, and prostaglandins (P < 0.05). Treatment with rosiglitazone, PPARγ-ago-
nist, enhanced CRH (P < 0.05) in both Tie2-sEH Tr and wild type (WT) mice. These data
demonstrate that endothelial over-expression of sEH (through changing the oxylipin profiles)
attenuates CRH, whereas inhibition ofω-hydroxylases and activation of PPARγ enhance it.
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Introduction
Cytochromes P450 (CYPs) metabolize arachidonic acid (AA) through two pathways to pro-
duce vasoactive oxylipins: CYP epoxygenases catalyze the epoxidation of AA to form epoxyei-
cosatrienoic acids (EETs) while CYP ω-hydroxylases hydroxylate AA to form ω-terminal
HETEs. EETs are produced in endothelial cells, and have numerous biological functions,
including hyperpolarization and relaxation of vascular smooth muscle cells by activating
large conductance Ca2+-activated K+ channels (BKCa) [1, 2]. EETs are short-lived [3], due to
rapid hydration by soluble epoxide hydrolase (sEH) to form dihydroxyeicosatrienoic acids
(DHETs). DHETs have been reported to have less, more, or equipotent vasodilatory effects to
EETs [4, 5]. While sEH is the main pathway of EET metabolism [6], some EETs, such as 5,6-
and 8,9-EET, are substrates for the cyclooxygenase (COX) pathway [7]. Different approaches
of targeting sEH to study the effects of EETs have been utilized, including genetic deletion [8–
11], endothelial expression [12, 13], and pharmacologic inhibition of sEH [11, 14] or CYP
epoxygenases [15]. Increased EET generation in mouse cardiomyocytes was shown to exert
cardioprotective effects against ischemia/reperfusion injury [8]. CYP4A is one of the ω-hyrox-
ylases involved in metabolizing AA to ω-terminal HETEs, including the potent vasoconstrictor
20-HETE (hydroxyeicosatetraenoic acid) [16]. In addition to regulating EET levels, sEH
expression also impacts CYP ω-hydroxylase pathway; as reported by Yadav et al., CYP4A level
was increased in the mesenteric arteries of mice with endothelial expression of sEH (Tie2-sEH
Tr mice) [12]. sEH activity also affects the levels of other arachidonic- and linoleic- acids
derived oxylipins, such as mid-chain hydroxyeicosatetraenoic acids (HETEs), prostaglandins
(PGs), epoxyoctadecaenoic acids (EpOMEs), and hydroxyoctadecadienoic acids (HODEs) [11,
17–20]. sEH inhibition was associated with an increased EET/DHET ratio and enhanced coro-
nary reactive hyperemia [11], whereas endothelial over-expression of sEH decreased EET/
DHET ratio and impaired endothelium-dependent vasodilation in the cerebral circulation in
mice [13]. Genetic variants, such as the human K55R variant allele, have increased sEH activity
and are associated with significantly higher risk of coronary heart disease in Caucasians [21].
EpOMEs, at physiological levels, are protective against hypoxia injury [22, 23]. Pretreatment
with 12,13-EpOME protected primary cultures of rabbit renal proximal tubular cells against
hypoxia/reoxygenation injury, whereas its metabolite 12,13-DiHOME failed to produce the
same protective effect [24]. DiHOMEs may have deleterious effects in the heart: at high con-
centrations, DiHOMEs are cytotoxic to cells in tissue culture [25]; at more physiological con-
centrations, DiHOMEs can be vasoconstrictive and cardiodepressive [9].
The heart responds to ischemia by temporarily increasing coronary blood flow [26], known
as reactive hyperemia (RH) or coronary RH (CRH). The increased blood flow associated with
CRH is protective, as it prevents injury or damage due to ischemia by increasing blood, nutri-
ents and oxygen supply to the deprived heart muscle [11]. Compromised CRH is observed in
several pathologic conditions affecting the coronary circulation, such as cardiac hypertrophy
[27], metabolic syndrome [28], unstable angina, myocardial infarction, and congestive heart
failure [29]. In addition to adenosine [27, 30, 31], nitric oxide (NO) [27], KATP channels [27]
and hydrogen peroxide (H2O2) [27], oxylipins, such as EETs, DHETs, EpOMEs, DiHOMEs,
mid-chain HETEs, prostanoids, and HODEs, may mediate CRH [11].
The vasoactive effects of oxylipins in CRH are not well studied. The actions of EETs may
be, at least in part, mediated by peroxisome proliferator-activated receptor-gamma (PPARγ)
[11, 32–35]. For example, EET-induced aortic relaxation in mice was mediated by PPARγ [10,
33]. The effects of sEH–over-expression, the associated changes in oxylipin profiles, and
the pharmacologic inhibition of ω-hydroxylases on CRH in response to short ischemia have
not been investigated. We hypothesized that sEH over-expression attenuates CRH through
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modulation in oxylipin profiles, whereas inhibition of ω-hydroxylases and activation of
PPARγ enhance CRH in isolated mouse hearts.
Materials and Methods
Animals
The generation of transgenic mice expressing Tie2-driven human sEH in endothelial cells on a
C57BL/6 genetic background (Tie2-sEH Tr) was described by Edin et al. [9]. Tie2-sEH Tr and
wild type (WT) mice were of the C57BL/6 genetic background, and were generously provided
by Dr. Darryl Zeldin, National Institute of Environmental Health Sciences/National Institutes
of Health (NIH). All animal care and experimentation protocols were approved and carried
out in accordance with the West Virginia University Institutional Animal Care and Use Com-
mittee and were in accordance with the principles and guidelines of the NIH’s Guide for the
Care and Use of Laboratory Animals. Both male and female mice (14–16 wks old) in equal ratio
were used in our study. Mice were maintained in cages with a 12:12 h light-dark cycle and free
access to standard chow (Cat #2018, Envigo, Indianapolis, IN) and water. Diet 2018 contains
6.2% fat by weight, including 0.7% palmitic, 0.2% stearic, 1.2% oleic %, 3.1% linoleic, and 0.3%
linolenic Acids.
Langendorff-Perfused Heart Preparation
We used the constant pressure mode of the Langendorff isolated heart perfusion as previously
described [11]. Tie2-sEH Tr and wild-type mice (14–16 wks.) were euthanized with sodium
pentobarbital (100 mg/kg body weight intra-peritoneally). Hearts were excised and immedi-
ately placed into heparinized (5 U/mL) ice-cold Krebs-Henseleit buffer containing (in mM)
119.0 NaCl, 11.0 glucose, 22.0 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2.0 pyru-
vate, and 0.5 EDTA. After removal of the lungs and tissue surrounding the heart, the aorta was
rapidly cannulated with a 20-gauge, blunt-ended needle and continuously perfused with 37˚C
buffer continuously bubbled with [95% O2]–[5% CO2] at a constant perfusion pressure of
80 mmHg. The left atrium was excised, and a water-filled balloon made of plastic wrap was
inserted into the left ventricle through the mitral valve. The balloon was connected to a pres-
sure transducer for continuous measurement of left ventricular developed pressure (LVDP)
and heart rate (HR). The heart was then immersed in a water-jacketed perfusate bath (37˚ C)
and left to beat spontaneously. Left ventricular diastolic pressure was adjusted to 2–5 mmHg.
A flow transducer was installed above the cannulated aorta for continuous measurement of
CF with an ultrasonic flow probe (Transonic Systems, Ithaca, NY). A Power–Lab Chart data
acquisition system (AD Instruments, Colorado Springs, CO) was used for data acquisition.
Heart function was allowed to stabilize for 30–40 min before initiation of CRH. Only hearts
whose CF increased by more than two fold after a 15-second total occlusion were included in
the analysis. This was to include only properly functioning hearts that were not damaged dur-
ing cannulation and baseline perfusion. Hearts with persistent arrhythmias or LVDP <80
mmHg were excluded.
Coronary Reactive Hyperemic Response
After stabilization for 30–40 minutes, baseline CF, HR, and LVDP were recorded. Hearts were
subjected to 15 seconds of total occlusion by closing the valve directly above the cannulated
heart to bring forth CRH. After CF returned to pre-CRH baseline levels, post-CRH baseline
CF, CF tracing, peak hyperemic flow (PHF), HR, LVDP, repayment volume (RV), and repay-
ment duration (RD) recordings were analyzed for each isolated heart. Investigational drugs
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were infused into the aortic perfusion line using a microinjection pump (Harvard Apparatus,
Holliston, MA) for 15 minutes, after which another CRH was induced and the same parame-
ters analyzed again. Drugs were infused at a rate equivalent to 1% of CF. The final concentra-
tions, after standardization of dose (0.01, 0.1, 1, & 10 μM) response for the various drugs used
in this study were 10 μM for rosiglitazone (PPARγ-agonist), t-AUCB (trans-4-[4-(3-adaman-
tan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (a selective sEH-inhibitor, University of Califor-
nia, Davis) [36], and 1 μM DDMS (dibromo-dodecenyl-methylsulfimide, CYP4A-blocker).
These concentrations are equal or lower than used in previous studies: rosiglitazone, 10 μM;
[11, 37], t-AUCB, 10 μM; [11, 35], DDMS, 1 μM [38].
Effect of t-AUCB on CRH Response
Isolated Tie2-sEH Tr and WT mouse hearts were subjected to 15 sec of total occlusion.
Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF, and RD) were
analyzed for each heart and averaged. t-AUCB was infused at a final concentration of 10 μM
and 1% of CF rate for 15 min, after which another CRH was induced and the same parameters
recorded again and analyzed.
LC–MS/MS Oxylipin Analysis
Levels of oxylipins (5,6-, 8,9-, 11,12- and 14,15-EET, 5,6-, 8,9-, 11,12- and 14,15-DHET, 5-,
8-, 9-, 11-, 12- and 15-HETE, 9,10- and 12,13-EpOME, 9,10- and 12,13-DiHOME, 9- and
13-HODE, 6-keto prostaglandin-F1α [6K-PG-F1α], PG-F2α, thromboxane B2 [TxB2], PGD2,
and PGE2) were quantified in pre- and post-CRH heart perfusates of Tie2-sEH Tr and WT
mice through liquid chromatography, tandem mass spectroscopy (LC-MS/MS) as described
previously [39]. Heart perfusates were collected for 2.5 min after the first 30 min of stabiliza-
tion and immediately after reperfusion. Hearts were immersed in 5 mL of warm (37˚C) Krebs-
Henseleit buffer with 5 μL of 10 μM t-AUCB to block further EET breakdown by sEH. Heart
perfusates were collected two times before ischemia (baseline) and pooled together as one sam-
ple and two times after ischemia and pooled together as another sample for LC-MS/MS analy-
sis. Samples were stored at –80˚C until processing. Samples were spiked with 30 ng PGE2-d4,
10,11- DiHN, and 10,11-EpHep (Cayman) as internal standards, mixed with 0.1 vol of 1% ace-
tic acid in 50% methanol, and extracted by serial passage through Oasis HLB C18 3mL col-
umns (Waters, Milford, MA, USA). Columns were washed twice with 0.1% acetic acid in 5%
methanol and eluted with methanol into glass tubes containing 6 μL of 30% glycerol in metha-
nol. The methanol was then evaporated under a stream of nitrogen gas, and the dried tubes
were frozen and stored at –80˚C until analysis. Online liquid chromatography of extracted
samples was performed with an Agilent 1200 Series capillary HPLC (Agilent Technologies,
Santa Clara, CA, USA). Separations were achieved using a Halo C18 column (2.7 mm, 10062.1
mm; MAC-MOD Analytical, Chadds Ford, PA), which was held at 50˚C. Mobile phase A was
85:15:0.1 water: acetonitrile: acetic acid. Mobile phase B was 70:30:0.1 acetonitrile: methanol:
acetic acid. Flow rate was 400 μL/min; Gradient elution was used. Mobile phase percentage B
and flow rate were varied as follows: 20% B at 0 min, ramp from 0 to 5 min to 40% B, ramp
from 5 to 7 min to 55% B, ramp from 7 to 13 min to 64% B. From 13 to 19 min the column
was flushed with 100% B at a flow rate of 550 μL/min. Samples were solvated in 50 μl of 30%
ethanol. The injection volume was 10 μL. Samples were analyzed in triplicate. Analyses were
performed on an MDS Sciex API 3000 equipped with a TurboIonSpray source (Applied Bio-
systems). Turbo desolvation gas was heated to 425˚C at a flow rate of 6 L/min. Negative ion
electrospray ionization tandem mass spectrometry with multiple reaction monitoring was
used for detection. Analyte quantification was performed using Analyst 1.5.1 software (AB
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Sciex, Ontario, Canada). Relative response ratios of analytes and respective internal standards
were compared to a standard curve of response ratios for each analyte. Lipid standards, which
are sensitive to oxidative degradation, were stored in 100% ethanol under argon and used
within 1 year of purchase from Cayman Chemical (Detroit, MI).
Effect of DDMS (ω-hydroxylases-inhibitor) on CRH Response
Isolated Tie2-sEH Tr and WT mice hearts were stabilized for 30–40 min, followed by 15 sec of
total occlusion. Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF
and RD) were analyzed for each heart and averaged. DDMS was infused at a final concentra-
tion of 1.0 μM for 15 minutes, after which the second CRH was induced. CRHs before and
after DDMS infusion were analyzed and compared.
Effect of Rosiglitazone on CRH Response
After stabilization, WT mouse hearts were subjected to 15 sec of total occlusion. As described
above, baseline CRH was induced in each mouse heart. Rosiglitazone (Cayman Chemical) was
infused at a final concentration of 10 μM for 15 min, followed by another CRH. CRHs before
and after rosiglitazone infusion were analyzed and compared.
Statistical and Data Analyses
Flow debt (baseline flow rate multiplied by occlusion duration) and RV (the integral of hyper-
emic area above the baseline flow) were calculated using “the integral relative to baseline”
function in the data pad of Lab-Chart 7.0 software. Since absolute coronary flow rates change
proportionally with heart mass, the RV and flow debt are presented as ml/g wet heart weight,
and baseline and peak flow rate data are presented as (mL.min–1.g wet heart weight–1). Values
are means ± standard error; n represents the number of animals. For data analysis, two-tailed
unpaired t-test was used for unpaired data analysis, and two-way ANOVA was used to com-
pare data between groups. Differences were considered statistically significant when P< 0.05.
Results
CRH Response
Effect of sEH endothelial expression on CRH response. Endothelial expression of sEH
attenuated CRH in Tie2-sEH Tr compared to WT mice. Compared to WT mice, Tie2-sEH Tr
mice had decreased repayment volume (10.7 ± 0.5 and 8.2 ± 0.6 mL/g, respectively; P< 0.05,
Fig 1A), decreased repayment duration (3.2 ± 0.2 and 2.4 ± 0.2 min, respectively; P< 0.05; Fig
1B), and decreased repayment/debt ratio (2.5 ± 0.2 and 1.9 ± 0.2, respectively; P< 0.05; Fig
1C). There was no statistically significant difference in body weight, heart weight, baseline CF,
LVPD, and HR between the two groups (P> 0.05; Fig 1D–1F). Table 1 lists the statistical
mean values and the standard error of the mean (SEM) for these parameters for the two groups
of mice. Time-matched control experiments with WT mouse hearts, employing three consecu-
tive inductions of CRH, showed no change in the CRH response and no difference in baseline
heart functions, including CF, LVDP, and HR (data not shown).
Effect of t-AUCB on CRH response in Tie2-sEH Tr and WT mice. The sEH-inhibitor,
t-AUCB, enhanced CRH in both Tie2-sEH Tr and WT mice. Repayment volume was
increased by 23% in WT mice (from 8.5 ± 0.7 to 10.5 ± 0.7 mL/g; P< 0.05) compared to 36%
in Tie2-sEH Tr mice (from 6.2 ± 0.6 to 8.5 ± 0.7 mL/g; P< 0.05, Fig 2A). Repayment duration
was increased by 43% in WT mice (from 2.2 ± 0.2 to 3.2 ± 0.3 min; P< 0.05) compared to 72%
in Tie2-sEH Tr mice (from 1.7 ± 0.2 to 3.0 ± 0.4 min; P< 0.05, Fig 2B). Also, repayment/debt
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ratio was increased by 23% in WT mice (from 2.5 ± 0.4 to 3.1 ± 0.4; P< 0.05) compared to
37% in Tie2-sEH Tr mice (from 1.9 ± 0.2 to 2.6 ± 0.2; P< 0.05, Fig 2C). There was no signifi-
cant difference between t-AUCB–treated WT and t-AUCB–treated Tie2-sEH Tr mice in the
above mentioned parameters based on the 2-way ANOVA analyses of interaction between the
2 variables: mouse strain and drug (t-AUCB). Baseline CF, LVPD, and HR were not different
between and within the two groups (P> 0.05; Fig 2D–2F).
Fig 1. Comparison of coronary reactive hyperemia (CRH) between Tie2-sEH Tr and WT. Repayment volume (A), repayment duration (B), and
repayment/debt ratio (C), were increased in Tie2-sEH Tr compared to WT mice (P < 0.05). Baseline CF (D), LVPD (E), and HR (F) were not different between
the two groups. * P < 0.05 versus WT. n = 12 per group.
doi:10.1371/journal.pone.0169584.g001
Table 1. Baseline functional data and coronary reactive hyperemia (CRH) parameters for sEH-over-
expressed (Tie2-sEH Tr) and wild type (WT) isolated mouse heart.
WT Tie2-sEH Tr
Age, weeks 16.8 ± 0.3 16.4 ± 0.1
Body weight, g 24.7 ± 1.3 23.6 ± 1.8
Heart weight, mg 103 ± 4.9 108 ± 5.6
Repayment volume, mL.g-1 10.7 ± 0.5 8.2 ± 0.6 *
Repayment duration, min 3.2 ± 0.2 2.4 ± 0.2 *
Baseline CF, ml.min-1.g-1 16.5 ± 0.8 16.9 ± 0.5
Debt volume, mL.g-1 4.3 ± 0.2 4.3 ± 0.1
Repayment / debt ratio 2.5 ± 0.2 1.9 ± 0.2 *
LVDP, mmHg 145 ± 10 161 ± 13
Heart rate, beat.min-1 394 ± 8 387 ± 17
* P < 0.05 versus WT. Values are means ± standard error. n = 12 per group.
doi:10.1371/journal.pone.0169584.t001
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Oxylipin Analysis of Heart Perfusate in WT and Tie2-sEH Tr Mice
Heart perfusate oxylipin levels were determined by LC–MS/MS. Perfusate samples were col-
lected at baseline after stabilization and after ischemia in WT and Tie2-sEH Tr mice. This
technique detected 3 out of the 4 EET regioisomers (8,9-, 11,12-, and 14,15-EETs), and their
corresponding metabolites (8,9-, 11,12-, and 14,15-DHETs). The measured EETs (8,9-, 11,12-,
and 14,15-EETs) were not significantly different between WT and Tie2-sEH Tr mice, (P>
0.05; Fig 3A–3C). Moreover, these EETs did not significantly change in response to ischemia
in either mouse strain (P> 0.05; Fig 3A–3C). For DHETs, a decreasing trend was noticed in
Tie2-sEH Tr compared to WT mice, which was significant in 8,9-, and 14,15-DHETs (P<
0.05; Fig 3D–3F). Ischemia had a decreasing effect on DHETs, which was significant only in
14,15-DHET in WT mice (P< 0.05; Fig 3F).
Linoleic acid (LA) epoxides (9,10- and 12,13-EpOMEs) were similar between WT and
Tie2-sEH Tr mice, (P> 0.05; Fig 4A). However, in both strains, these epoxides decreased in
response to ischemia (P< 0.05; Fig 4A). The corresponding 12, 13-DiHOME level was lower
in Tie2-sEH Tr compared to WT mice (P< 0.05; Fig 4B), and was decreased in response to
ischemia in both mouse groups (P< 0.05; Fig 4B). The other DiHOME (9,10-DiHOME) did
not change due to ischemia or to sEH endothelial expression (P> 0.05; Fig 4B).
Mid-chain HETEs (5-, 8-, 11-, 12-, and 15-HETEs) were detected in WT and Tie2-sEH
Tr mouse heart perfusates before and after ischemia. In Tie2-sEH Tr mice, the levels of 5-, 8-,
11-, 12-, and 15-HETE were significantly decreased compared to WT mice at baseline and
Fig 2. Effect of the sEH-inhibitor (t-AUCB, 10 μM) on coronary reactive hyperemia (CRH) in Tie2-sEH Tr and WT mice. The sEH-inhibitor, t-AUCB,
enhanced CRH in both Tie2-sEH Tr and WT mice. Repayment volume (A), repayment duration (B), and repayment/debt ratio (C) were increased in both
strains. Repayment volume was decreased more in Tie2-sEH Tr compared to WT mice. Baseline CF (D), LVPD (E), and HR (F) were not different between
the two groups. * P < 0.05 versus WT. # P < 0.05 versus t-AUCB–treated WT. n = 8 per group.
doi:10.1371/journal.pone.0169584.g002
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post-ischemia (P< 0.05; Fig 5A–5E). Post-ischemic levels of 5-, and 15-HETEs were not sig-
nificantly decreased in Tie2-sEH Tr compared to WT mice (P> 0.05; Fig 5A and 5E). Ische-
mia also had a decreasing effect on mid-chain HETEs in WT (reaching significant levels for 5-,
11-, 12-, and 15-HETEs) and Tie2-sEH Tr mice (reaching significant levels for 5-, 11-, 12-, and
15-HETEs) (P< 0.05; Fig 5A–5E).
Other LA hydroxylated metabolites, 9- and 13-HODEs, were not significantly different
between WT and Tie2-sEH Tr mice at baseline or post-ischemia (P> 0.05; Fig 6). However,
in both WT and Tie2-sEH Tr, 9- and 13-HODEs decreased in response to ischemia (P< 0.05;
Fig 6).
The levels of 6K-PG-F1α, PG-F2α, PG-D2, and PG-E2 were also detected by our LC–MS/MS
(Fig 7). For these PGs, a decreasing trend in their level was noticed in Tie2-sEH Tr compared
to WT mice, which was significant at baseline in PG-E2 (P< 0.05; Fig 7D), and post-ischemia
in PG-F2α, and PG-E2 (P< 0.05; Fig 7C and 7D). Also, ischemia decreased the level of these
Fig 3. LC–MS/MS analysis for EETs (8, 9–, 11, 12–, and 14, 15–) and DHETs (8, 9–, 11, 12–, and 14, 15–) levels in WT and Tie2-sEH Tr mouse heart
perfusates at baseline and post-ischemia. 8,9-EET (A), 11,12-EET (B), and 14,15-EET (C) were not significantly different between WT and Tie2-sEH Tr
mice. Also, the levels of EETs were not affected in response to ischemia in either mouse strain (P > 0.05). 8,9-DHET (D), and 14,15-DHET (F) were
decreased in Tie2-sEH Tr compared to WT mice (P < 0.05), whereas 11,12-DHET (E) was not significantly different between the two groups (P > 0.05). Also,
14,15-DHET (F) was decreased in response to ischemia in Tie2-sEH Tr (P < 0.05). * P < 0.05 versus baseline WT. # P < 0.05 versus WT post-ischemia.
n = 12 WT and 14 Tie2-sEH Tr.
doi:10.1371/journal.pone.0169584.g003
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PGs in both strains, but was significant in PG-F203B0031, and PG-E2 (P< 0.05; Fig 7C and
7D)
Effect of DDMS (ω-hydroxylases-inhibitor) on CRH Response
DDMS enhanced CRH in both Tie2-sEH Tr and WT mice. Repayment volume was increased
by 33% in WT mice (from 8.6 ± 0.2 to 11.4 ± 1.5 mL/g; P< 0.05) compared to 63% in Tie2-
sEH Tr mice (from 6.1 ± 0.2 to 9.9 ± 0.8 mL/g; P< 0.05, Fig 8A). Repayment duration was
increased by 80% in WT mice (from 2.6 ± 0.2 to 4.6 ± 0.7 min; P< 0.05) compared to 62% in
Tie2-sEH Tr mice (from 1.9 ± 0.2 to 3.1 ± 0.4 min; P< 0.05, Fig 8B). Also, repayment/debt
ratio was increased by 48% in WT mice (from 2.9 ± 0.4 to 4.3 ± 0.6; P< 0.05) compared to
69% in Tie2-sEH Tr mice (from 2.5 ± 0.3 to 4.1 ± 0.7; P< 0.05, Fig 8C). There was no signifi-
cant difference between DDMS–treated WT and DDMS–treated Tie2-sEH Tr mice in the
above mentioned parameters based on the 2-way ANOVA analyses of interaction between the
2 variables: mouse strain and drug (DDMS). Baseline CF, LVPD, and HR were not different
between and within the two groups (P> 0.05; Fig 8D–8F).
Effect of rosiglitazone (PPARγ agonist) on CRH Response
Rosiglitazone enhanced CRH in both Tie2-sEH Tr and WT mice. Repayment volume was
increased by 19% in WT mice (from 9.8 ± 0.3 to 11.7 ± 0.6 mL/g; P< 0.05) compared to 20%
in Tie2-sEH Tr mice (from 8.6 ± 0.4 to 10.3 ± 0.6 mL/g; P< 0.05, Fig 9A). Repayment dura-
tion was increased by 21% in WT mice (from 3.1 ± 0.4 to 3.7 ± 0.6 min; P< 0.05), but not in
Tie2-sEH Tr mice (P> 0.05, Fig 9B). Repayment/debt ratio, baseline CF, LVPD, and HR were
not different between and within the two groups (P> 0.05; Fig 9C–9F).
Discussion
Endothelial-specific over-expression of human sEH (Tie2-sEH Tr) in C57BL/6 mice decreased
CRH in an isolated heart model in response to brief ischemia. Endothelial over-expression of
Fig 4. LC–MS/MS analysis of EpOME and DiHOME levels in WT and Tie2-sEH Tr mouse heart perfusates at baseline and post-ischemia. 9,10- and
12,13-EpOMEs (A) were decreased in response to ischemia in both WT and Tie2-sEH Tr mice (P < 0.05), but were not different between the two groups
(P > 0.05). 12, 13-DiHOME (B) level was decreased in Tie2-sEH Tr compared to WT mice (P < 0.05), and was decreased in response to ischemia in both
mouse groups (P < 0.05). 9,10-DiHOME level (B) did not change due to ischemia or to sEH endothelial expression (P > 0.05). * P < 0.05 versus baseline WT.
# P < 0.05 versus WT post-ischemia. n = 12 WT and 14 Tie2-sEH Tr.
doi:10.1371/journal.pone.0169584.g004
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sEH was also associated with changes in arachidonic and linoleic acids-derived oxylipin pro-
files. The relationship among sEH over-expression, subsequent oxylipin changes, and modula-
tion of CRH in isolated mouse hearts is not known. Therefore, we designed this study to
investigate the role of sEH over-expression and the associated oxylipin changes in the modula-
tion of CRH using isolated WT and Tie2-sEH Tr mouse hearts. Our data demonstrated that:
1) Endothelial over-expression of sEH decreased CRH; 2) Inhibition of sEH by t-AUCB
reversed the decrease in CRH associated with sEH–over-expression in Tie2-sEH Tr mice; 3)
Endothelial over-expression of sEH was associated with changes in some oxylipin profiles,
including decrease in DHETs, EpOMEs, DiHOMEs, and mid-chain HETEs; 4) Inhibition of
ω-hydroxylases (by DDMS) enhanced CRH in WT and Tie2-sEH Tr mice; 5) The PPARγ ago-
nist rosiglitazone enhanced CRH in WT and Tie2-sEH Tr mice.
Endothelial over-expression of human sEH decreased CRH after brief ischemia in Tie2-
sEH Tr mice compared to WT mice. Brief ischemia in the heart is followed by CRH [26], which
protects the heart against the potential ischemia damage [11]. The significance of CRH was
confirmed by several studies which linked compromised CRH with different cardiovascular
Fig 5. LC–MS/MS analysis of 5-, 8-, 11-, 12- and 15-HETE levels in WT and Tie2-sEH Tr mouse heart perfusates at baseline and post-ischemia. In
Tie2-sEH Tr mice, the levels of 5-HETE (A), 8-HETE (B), 11-HETE (C), 12-HETE (D), 15-HETE (E), were decreased compared to WT mice at baseline and
post-ischemia (P < 0.05). In both WT and Tie2-sEH Tr mice, post-ischemic levels of 5-, 11-, 12-, and 15-HETEs were decreased compared to baseline levels
(P < 0.05). * P < 0.05 versus baseline WT. # P < 0.05 versus WT post-ischemia.ФP < 0.05 versus baseline Tie2-sEH Tr. n = 12 WT and 14 Tie2-sEH Tr.
doi:10.1371/journal.pone.0169584.g005
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pathologies [27, 28]. EETs were suggested, among other oxylipins, to mediate CRH in mice in
response to brief ischemia [11]. Hydration by sEH is the main metabolic pathway responsible
for converting EETs to their primary metabolites, the DHETs [40]. Endothelial over-expression
of human sEH, which was associated with increased conversion of EETs to DHETs, impaired
endothelium-dependent vasodilation in the cerebral circulation in mice [13]. Lee et al. reported
that Caucasian carriers of the K55R variant, with higher sEH activity in vivo, had significantly
higher risk of incident coronary heart disease [21]. These reports reiterate the well-established
beneficial cardiovascular effects of EETs [10, 25, 40–42], including vasodilation in the kidney
preglomerular vasculature [43], intestines [44], and brain [45], and protection against ischemia/
reperfusion injury [8]. Although DHETs are generally viewed as less active compared to EETs,
some studies have reported equal or even more potent vasodilatory effect for DHETs compared
to EETs [4, 5, 46]. For example, 11,12- and 14,15-DHETs were shown to cause vasodilation in
isolated human coronary arteries [5] and bovine coronary arteries [4] respectively. The relative
potency of these EETs and DHETs was also compared, with 11,12-DHET being equipotent
to 11,12-EET [5], and 14,15-DHET being fivefold less potent than 14,15-EET [4]. We have
Fig 6. LC–MS/MS analysis of HODEs in WT and Tie2-sEH Tr mouse heart perfusates at baseline and post-ischemia. In both WT and Tie2-sEH Tr, 9-
and 13-HODEs decreased in response to ischemia (P < 0.05). However, they were not significantly different between the two groups at baseline or post-
ischemia (P > 0.05). * P < 0.05 versus baseline WT. # P < 0.05 versus WT post-ischemia. n = 12 WT and 14 Tie2-sEH Tr.
doi:10.1371/journal.pone.0169584.g006
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previously shown that targeting sEH, through pharmacologic inhibition [11] or genetic deletion
[11], was associated with enhanced CRH. In this study, pharmacologic inhibition of sEH, by
t-AUCB, not only enhanced CRH as previously shown, it also reversed the decrease in CRH
observed in Tie2-sEH Tr mice, and increased it to a level comparable to that in WT mice. This
approach of targeting EETs pathway from different angles strongly supports previous [11] as
Fig 7. LC–MS/MS analysis of 6-keto-PG-F1α, PG-F2α, PG-D2, and PG-E2 in WT and Tie2-sEH Tr mouse heart perfusates at baseline and post-
ischemia. The levels of PG-D2 (A) and 6-Keto-PG-F1α (B) were not significantly changed due to ischemia or between Tie2-sEH Tr and WT mice (P > 0.05).
In both Tie2-sEH Tr and WT mice, PG-F2α (C) was decreased post-ischemia (P < 0.05). PG-E2 (D) was decreased at baseline and post-ischemia in Tie2-sEH
Tr compared to WT mice (P < 0.05), and it was also decreased in response to ischemia in Tie2-sEH Tr mice (P < 0.05). * P < 0.05 versus baseline WT.
# P < 0.05 versus WT post-ischemia.Ф P < 0.05 versus baseline Tie2-sEH Tr. n = 12 WT and 14 Tie2-sEH Tr.
doi:10.1371/journal.pone.0169584.g007
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well as current findings of sEH involvement in CRH, where inhibiting or deleting sEH [11]
enhances CRH, and over-expressing it attenuates CRH.
Our functional data in this study agree with our previously published data [11] in terms of
the effect of sEH on CRH. However, the oxylipin data are not as congruent. In the current
study, endothelial-specific over-expression of sEH (Tie2-sEH Tr) was, unexpectedly, associ-
ated with decreased levels of DHETs compared to WT mice. DHETs are metabolic products of
EETs’ hydrolysis by sEH. Our lab has reported that global deletion of sEH (sEH–/–mice) [11]
and pharmacologic inhibition by t-AUCB [11] resulted in decreased DHETs. In contrast to
our findings in this study, over-expressing sEH in Tie2-sEH Tr mice resulted in decreased
plasma level of 11,12- and 14,15-DHETs compared to WT [13]. Possible explanations for these
different results are the different source of the samples: Zhang et al. used plasma samples,
whereas we used heart perfusate samples. Another likely possibility is that increasing sEH only
in endothelial cells has merely a small effect on total cardiac EET hydrolysis. Cardiomoyctes,
which highly express both CYP epoxygenases and sEH [47] comprise 60% of all heart cells
[48]. While endothelial cells (ECs) from Tie2-sEH Tr mice have increased endothelial sEH
expression and EET hydrolysis [9, 49] (they represent less than 10% of all heart cells [48].
Thus, the effect of endothelial sEH overexpression on total EET and DHET levels in the heart
may be minor in the context of hearts with otherwise WT sEH expression. While not altering
global cardiac levels of EETs or DHETs, increased sEH in endothelial cells of Tie2-sEH Tr
hearts may increase the hydrolysis of EETs in endothelial cells and reduce their paracrine,
vasodilatory effects on smooth muscle. We previously reported that global deletion of sEH
Fig 8. Effect of the CYP4A-blocker (DDMS, 1 μM) on coronary reactive hyperemia (CRH) in Tie2-sEH Tr and WT mice. The CYP4A-blocker, DDMS,
enhanced CRH in both Tie2-sEH Tr and WT mice. Repayment volume (A), repayment duration (B), and repayment/debt ratio (C) were increased in both
strains. Repayment volume was decreased more in Tie2-sEH Tr compared to WT mice. Baseline CF (D), LVPD (E), and HR (F) were not different between
the two groups. * P < 0.05 versus WT. # P < 0.05 versus DDMS–treated WT. n = 8 per group.
doi:10.1371/journal.pone.0169584.g008
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(sEH–/–mice) increased 14,15-EET in heart perfusate samples [11], whereas in this study no
difference was found in EET levels between hearts from WT and Tie2-sEH Tr mice. Addition-
ally, the short half-life of EETs [3], and the limited over-expression of sEH to the endothelium
in Tie2-sEH Tr mice may explain the lack of change in EET levels in our study. Therefore, the
decreased levels of DHETs in our data, which indicates reduced DHET-mediated vasodilation
as reported previously [4, 5], may explain the decreased CRH in Tie2-sEH Tr compared to
WT mice.
In early studies, the role of sEH in cardiovascular biology was primarily linked to its role in
EET hydrolysis; however, sEH also plays a central role in the metabolism and actions of other
arachidonic-, linoleic- and omega-3-derived oxylipins [24]. Accordingly, we have expanded
oxylipin analyses to include more oxylipins besides EETs and DHETs. The other oxylipins we
examined are EpOMEs, which are hydrolyzed to DiHOMEs by sEH. EpOMEs and DiHOMEs
are found in abundance in mouse tissues and plasma since their parental fatty acid, linoleic
acid, comprises 50% of all fatty acids in our mouse diets. We expected either increase or no-
change in DiHOMEs in our Tie2-sEH Tr mice; however, we found no change in 9,10-DiHOME
and a decrease in 12,13-DiHOME in Tie2-sEH Tr versus WT mice. In addition, EpOME levels
were not different between the two mouse strains. In contrast, we previously found that global
deletion of sEH (sEH–/–mice) [11] and pharmacologic inhibition of sEH by t-AUCB [11]
increased EpOME, decreased DiHOMEs, and increased EpOME/DiHOME ratio. In these stud-
ies, the altered EpOME/DiHOME ratio may have contributed to the enhancement of CRH [11].
On the other hand, decreased EpOME/DiHOME ratio in the plasma of Tie2-sEH Tr mice was
associated with impaired endothelium-dependent vasodilation in the cerebral circulation [13].
Fig 9. Effect of the PPARγ-agonist (rosiglitazone, 10 μM) on coronary reactive hyperemia (CRH) in Tie2-sEH Tr and WT mice. The PPARγ-agonist,
rosiglitazone, enhanced CRH in both Tie2-sEH Tr and WT mice. Repayment volume (A), and repayment/debt ratio (C) were increased in both strains.
Repayment duration (B) was increased in WT mice, but not in Tie2-sEH Tr mice. Repayment volume was decreased more in Tie2-sEH Tr compared to WT
mice. Baseline CF (D), LVPD (E), and HR (F) were not different between the two groups. * P < 0.05 versus WT. # P < 0.05 versus rosiglitazone–treated WT.
n = 8 per group.
doi:10.1371/journal.pone.0169584.g009
Soluble Epoxide Hydrolase Attenuates Coronary Reactive Hyperemia
PLOS ONE | DOI:10.1371/journal.pone.0169584 January 5, 2017 14 / 21
These data suggest that a high EpOME/DiHOME ratio may have a positive role in mediating
vasodilation, whether the ratio is increased due to elevated EpOMEs [11] and / or decreased
DiHOMEs [11, 13]. Compared to EETs, the functions of EpOMEs and DiHOMEs are less well-
defined [17]; however, a few studies suggest that EpOMEs, at physiological levels, protected
against hypoxia/reoxygenation injury [22, 23]. Konkel et al. demonstrated that pretreatment
with 12,13-EpOME protected primary cultures of rabbit renal proximal tubular cells against
hypoxia/reoxygenation injury, whereas its metabolite 12,13-DiHOME failed to produce the
same protective effect [24]. In contrast, the hydrated metabolites, DiHOMEs, have shown dele-
terious effects, including cytotoxic, vasoconstrictive and cardiodepressive properties [9, 25]. In
our study, the unchanged level of EpOMEs and the modest decrease in 12,13-DiHOME in
Tie2-sEH Tr may suggest that they did not contribute much to the decreased CRH in Tie2-sEH
Tr compared to WT mice.
Mid-chain (5-, 8-, 11-, 12- and 15-) HETE levels were decreased in Tie2-sEH Tr compared
to WT mice and in response to ischemia. Mid-chain HETEs are produced from AA by allylic
oxidation by lipoxygenase [24] and by bis-allylic oxidation by CYP1B1 [50]. They were shown
to have vasoconstrictive and pro-inflammatory effects [50, 51]. Also, the increased formation
of mid-chain HETEs was involved in cardiovascular dysfunction [52–55]. Our finding that
mid-chain HETEs were decreased in both mouse strains post-ischemia is in agreement with
our previously published data [11]. However, our finding that CRH was decreased in Tie2-sEH
Tr mice is not supported by the decreased levels of the vasoconstrictive mid-chain HETEs in
the same mice. This surprising result also contrasts with previous findings from our lab in
which sEH inhibition was accompanied by decreased mid-chain HETEs in the heart perfusate
of WT mice [11]. However, to the best of our knowledge, the level of mid-chain HETEs in
Tie2-sEH Tr mice has not been evaluated in any tissue or fluid, including the heart perfusate.
Changes in the level of AA metabolites in response to genetic manipulation of relevant
enzymes have been reported [11, 18]. This unexpected finding could be reconciled with our
functional finding of decreased CRH in Tie2-sEH Tr mice if we consider another important
finding: the level of CYP4A. CYP4A is an ω-hyroxylase involved in metabolizing AA to the
potent vasoconstrictor 20-HETE [16]. Yadav et al. has recently reported that CYP4A level was
increased in the mesenteric arteries of Tie2-sEH Tr mice [12]. These data suggest that while
the decrease in mid-chain HETEs observed in the heart perfusates of Tie2-sEH Tr mice should
have enhanced CRH, the reported increased expression of CYP4A in the same mice may have
overridden the effect of decreased mid-chain HETEs and caused a net effect of decreased
CRH.
In addition to EpOMEs, HODEs are the other oxylipins derived from linoleic acid (LA)
through hydroxylation by CYP epoxygenases or lipoxygenases [24]. The detected two HODE
isomers, 9-, and 13-HODE, were similar in Tie2-sEH Tr and WT. The physiologic functions
of HODEs are not widely investigated [24], though 9-, and 13-HODE appear to have some
opposing effects [56]. 13-HODE has been suggested to have an anti-inflammatory role [57–
61], while 9-HODE was described as pro-inflammatory [62, 63]. Similar to our findings,
Luria et al. reported no change in mouse urinary samples of 9– and 13–HODE when sEH
was deleted [17]. However, heart perfusate samples from the same strain (sEH–/–mice) had
increased level of 13–HODE compared to WT [11]. Since endothelial over-expression of sEH
in Tie2-sEH Tr mice did not change the level of HODEs, we do not expect that changes in
HODEs played any role in the decreased CRH noticed in Tie2-sEH Tr compared to WT mice.
Endothelial over-expression of sEH in Tie2-sEH Tr mice resulted in significant changes in
prostanoid levels, including PG-E2, and PG-F2α. Although PG-F1α, and PG-D2, had a decreas-
ing trend in Tie2-sEH Tr mice, the difference was not significant. PGs have generally been
described as pro-inflammatory [64], still, recent reports indicate that some, such as PG-D2 and
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PG-E2, are anti-inflammatory by up-regulating cAMP and inducing secretion of the anti-
inflammatory IL-10 [64, 65]. 6-keto-PG-F1α is the non-active metabolite of prostacyclin
(PG-I2) [64]. Similar to these findings, published reports by our lab and others have demon-
strated that pharmacologic inhibition or genetic deletion of sEH were accompanied by
decreased prostanoids [11, 19, 20]. Hellmann et al. suggested that prostaglandins are not
involved in post-occlusive reactive hyperemia in the skin [66]. Despite the observed decrease
in the level of some PGs in Tie2-sEH Tr mice, the lack of evidence for the involvement of PGs
in reactive hyperemia and their variable effects on inflammation suggest that PG changes did
not likely contribute to the decrease in CRH in Tie2-sEH Tr mice.
As mentioned earlier, ω-terminal HETEs are generated from AA by CYP ω-hydroxylases,
primarily CYP4A and CYP4F subfamilies, with 20-HETE being the primary product [16].
20-HETE is involved with the renin-angiotensin system to promote hypertension, vasocon-
striction, and vascular dysfunction [67, 68]. Weldmann et al. suggested that 20-HETE contrib-
utes to postmenopausal hypertension in spontaneously hypertensive rats (SHR) [69]. Blocking
20-HETE synthesis by 1-aminobenzotriazole inhibited renal production of 20-HETE, and
reduced mean arterial pressure in old female SHR [69]. The changes in the renal production of
20-HETE was consistent with the expression level of CYP4A protein [70]. In this study, inhib-
iting ω-hydroxylases by DDMS enhanced CRH in Tie2-sEH Tr and WT mice, however, the
percent increase in CRH in Tie2-sEH Tr mice (63%) was higher than that in WT mice (33%),
which suggests a possible increased activity of ω-hydroxylases in Tie2-sEH Tr compared to
WT mice. This in turn could lead to higher levels of 20-HETE. This possibility is supported by
the finding that CYP4A’s expression was increased in the mesenteric arteries of Tie2-sEH Tr
mice [12]. The levels of 20-HETE were too low to be detected in heart perfusates from WT or
Tie2-sEH Tr mice. Upregulation of CYP4A [12], may contribute to reduced CRH in Tie2-sEH
Tr compared to WT mice. As mentioned earlier, the temporary pharmacological inhibition of
sEH could not completely restore CRH in Tie2-sEH Tr to that in WT mice. This suggests that
other mechanisms or mediators, besides sEH, could be involved in decreasing CRH. One such
mechanism is the upregulation of CYP4A reported in Tie2-sEH Tr mice and the possible
increase in 20-HETE. Improved techniques for detection of the level of 20-HETE in mice are
required to better characterize the role it may play in CRH in WT or Tie2-sEH Tr hearts. Nev-
ertheless, our data suggest that dual inhibition of sEH and omega hydroxylases may have a syn-
ergistic effect to enhance CRH.
This study also showed that CRH was increased by rosiglitazone, a PPARγ-agonist. PPAR
agonists are well known inducers of both sEH [71] and omega hydroxylases [72]. Due to the
short treatment periods, and that such induction would likely reduce CRH, we believe induc-
tion of these enzymes by rosiglitazone was minimal. Previously, we suggested that PPARγ may
mediate CRH downstream of the CYP epoxygenase-EET pathway [11]. Other studies indi-
cated that PPARγ receptors could mediate EETs’ effects [32–35]. Liu et al. suggested that selec-
tive sEH inhibition, which increases the retention of EETs, potentiates the anti-inflammatory
effect in endothelial cells by PPARγ activation [32]. Although our results suggest that PPARγ
receptors are involved in modulating CRH in both Tie2-sEH Tr and WT mice, they also show
that the role these nuclear receptors play in CRH is comparable between the two mouse strains,
and that endothelial expression of sEH does not impact their role compared to that in WT
mice.
In summary, the findings of this study suggest that endothelial over-expression of sEH
decreases CRH possibly through attenuating the CYP epoxygenase pathway and augmenting
the CYP ω-hydroxylase pathway, as reflected by the changes in AA–derived oxylipins
(decreased DHETs, decreased mid-chain HETEs, and decreased PGs) and LA–derived oxyli-
pins (decreased 12,13-DiHOME, and no change in HODEs). The effects of sEH–over-
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expression on these pathways might have collectively accounted for the observed decrease in
CRH. Changes in CRH are partially mediated by PPARγ activation in the two studied mouse
strains, as demonstrated by the enhanced CRH after PPARγ-agonist treatment. Therefore, we
conclude that sEH–over-expression attenuates, whereas ω-hydroxylases–inhibition and activa-
tion of PPARγ enhance CRH.
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